Adult: For the remission of various symptoms caused by respiratory obstructive disturbances: As inhalation solution: 30-50 mcg (0.3-0.5 mL) via nebuliser. Dosage must be adjusted according to the severity of symptoms and the patient's age. Child: For the remission of various symptoms caused by respiratory obstructive disturbances: As inhalation solution: 10-30 mcg (0.1-0.3 mL) via nebuliser. Dosage must be adjusted according to the severity of symptoms and the patient's age.
Oral Asthma, Bronchitis, Pulmonary emphysema
Adult: For the relief of dyspnoea or other symptoms caused by respiratory obstructive disturbance: As tab or syrup: 50 mcg once daily before bedtime or bid (morning and before bedtime). Dosage must be adjusted according to the severity of symptoms and the patient's age. Child: For the relief of dyspnoea or other symptoms caused by respiratory obstructive disturbance: <6 years As syrup: 1.25 mcg/kg bid (morning and before bedtime) or tid (morning, early afternoon, and before bedtime); ≥6 years As tab or syrup: 25 mcg once daily before bedtime or bid (morning and before bedtime). Dosage must be adjusted according to the severity of symptoms and the patient's age.
What are the brands available for Procaterol in Malaysia?
Meptin
Administration
Procaterol May be taken with or without food.
Special Precautions
Patient with CV disease (e.g. arrhythmia, heart failure, hypertension), hyperthyroidism, diabetes mellitus, hypokalaemia. Not indicated for initial rescue treatment of acute episodes of bronchospasm. Procaterol should only be used as adjunct therapy in asthma when symptoms are inadequately controlled by inhaled corticosteroids or other asthma medications. Children and elderly. Pregnancy and lactation.
Adverse Reactions
Significant: Shock or anaphylactoid reaction; increased blood pressure or heart rate, increased risk of arrhythmias; exacerbation of hyperthyroidism or diabetes mellitus; significant hypokalaemia. Cardiac disorders: Palpitations, tachycardia. Gastrointestinal disorders: Nausea, vomiting, dry mouth, gastric discomfort. General disorders and administration site conditions: Generalised malaise or fatigue. Nervous system disorders: Headache, tremor, dizziness, drowsiness, numbness of limbs. Psychiatric disorders: Insomnia. Respiratory, thoracic and mediastinal disorders: Nasal congestion. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Facial flushing. Potentially Fatal: Cardiac arrhythmias or arrest (continuous excessive doses).
Monitoring Parameters
Monitor blood pressure, heart rate, serum glucose, and lung function tests. Closely monitor serum potassium levels, especially in hypoxic patients. Assess for signs and symptoms of shock or anaphylactoid reactions.
Management: Symptomatic and supportive treatment. Perform gastric lavage to remove unabsorbed drug. In case of serious tachycardiac arrhythmia, careful administration of β-blockers (e.g. propranolol) may be considered.
Drug Interactions
May result in aggravated decrease in serum potassium levels and cardiac adverse effects (e.g. arrhythmia) with xanthine derivatives (e.g. aminophylline, theophylline), corticosteroids (e.g. betamethasone, hydrocortisone), and diuretics (e.g. furosemide). Potentially Fatal: Catecholamines (e.g. epinephrine, isoprenaline) potentiate the adrenoceptor stimulating effects of procaterol, which may lead to arrhythmias or cardiac arrest.
Lab Interference
May suppress skin reactions in allergen testing.
Action
Description: Overview: Procaterol is a long-acting sympathomimetic bronchodilator. Mechanism of Action: Procaterol selectively stimulates the β2-adrenergic receptors present on the bronchial smooth muscle and produces bronchodilative action. Pharmacokinetics: Absorption: Time to peak plasma concentration: 1.4 ± 0.82 hours. Metabolism: Metabolised in the liver by CYP3A4 mainly via glucuronide conjugation into desisopropyl procaterol. Excretion: Excretion: Via urine (0.48% as desisopropyl procaterol; 15.7% as unchanged drug; 23.6% as glucuronide). Half-life elimination: 3.83 ± 0.93 hours.
Chemical Structure
Procaterol Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 688563, Procaterol. https://pubchem.ncbi.nlm.nih.gov/compound/Procaterol. Accessed Sept. 26, 2025.
Storage
Oral: Tab: Store below 30°C. Protect from light and moisture. Syrup: Store below 25°C. Protect from light.
Inhalation: Inhalation solution: Store below 25°C. Protect from light.
R03AC16 - procaterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. R03CC08 - procaterol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
References
Brayfield A, Cadart C (eds). Procaterol Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/09/2025.Brezu 5 mcg/mL Syrup (Otsuka [Philippines] Pharmaceutical, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/09/2025.Meptin 50 mcg and 25 mcg Tab, 5 mcg/mL Syrup (Otsuka [Philippines] Pharmaceutical, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 08/09/2025.Meptin 50 mcg Tab and 25 mcg Minitab (Otsuka Indonesia PT). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 08/09/2025.Meptin Inhalation Solution (Otsuka Indonesia PT). MIMS Indonesia. http://www.mims.com/indonesia. Accessed 08/09/2025.Procaterol. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 08/09/2025.
Sign Out
Continue with Google